Stada has welcomed “an exceptionally successful financial year” for 2019, with double-digit sales growth largely driven by the successful launch of a ready-to-use, differentiated formulation of Janssen’s Velcade (bortezomib) in 14 European countries midway through the second quarter.
The German firm “broadly outperformed its competitors and achieved substantial market-share gains in almost all of its core markets during...






